41 related articles for article (PubMed ID: 36117108)
1. Concordance of Abundance for Mutational
Wang Y; Liu H; Yu N; Xiang X
Curr Oncol; 2023 Sep; 30(9):8464-8476. PubMed ID: 37754531
[TBL] [Abstract][Full Text] [Related]
2. Valproic acid increased the efficacy of EGFR TKIs on EGFR/TP53 co-mutated lung cancers and downregulated mutant-p53 levels.
Hu M; Cheng H; Yang Y; Xu L
Mol Carcinog; 2024 Feb; 63(2):275-285. PubMed ID: 37877748
[TBL] [Abstract][Full Text] [Related]
3. Cancer mutational signatures identification in clinical assays using neural embedding-based representations.
Yaacov A; Ben Cohen G; Landau J; Hope T; Simon I; Rosenberg S
Cell Rep Med; 2024 Jun; 5(6):101608. PubMed ID: 38866015
[TBL] [Abstract][Full Text] [Related]
4. [Exploring Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity: An Emerging Issue from Bench to Bedside].
Collotta D; Aimaretti E; Collino M
G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007828
[TBL] [Abstract][Full Text] [Related]
5. Epidemiological and Therapeutic Analyses in Lung Cancer Patients Over 80 Years Old in the Hokushin Region: A Retrospective Hospital Administrative Database Study.
Koizumi T; Nishino Y; Takiguchi T; Kanda S; Otsuki K; Tanaka Y; Tomita R; Araki T; Hayashi R; Yasumoto K; Uramoto H; Hirono Y; Makino T; Nakada M; Yano S
Clin Lung Cancer; 2023 Mar; 24(2):145-152. PubMed ID: 36639281
[TBL] [Abstract][Full Text] [Related]
6. Safety, Pharmacokinetic and Clinical Activity of Intrathecal Chemotherapy With Pemetrexed via the Ommaya Reservoir for Leptomeningeal Metastases From Lung Adenocarcinoma: A Prospective Phase I Study.
Li H; Zheng S; Lin Y; Yu T; Xie Y; Jiang C; Liu X; Qian X; Yin Z
Clin Lung Cancer; 2023 Mar; 24(2):e94-e104. PubMed ID: 36588048
[TBL] [Abstract][Full Text] [Related]
7. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
Dieleman E; van der Woude L; van Os R; van Bockel L; Coremans I; van Es C; De Jaeger K; Knol HP; Kolff W; Koppe F; Pomp J; Reymen B; Schinagl D; Spoelstra F; Tissing-Tan C; van der Voort van Zyp N; van der Wel A; Wijsman R; Dielwart M; Wiegman E; Damhuis R; Belderbos J
Clin Lung Cancer; 2023 Mar; 24(2):130-136. PubMed ID: 36572596
[TBL] [Abstract][Full Text] [Related]
8. The Value of Radiotherapy in Patients With Resectable Stage IIIA Non-Small-Cell Lung Cancer in the Era of Individualized Treatment: A Population-Based Analysis.
Liu B; Wang Z; Zhao H; Gao S; Wang H; Zhang Y; Fan K; Tao R; Li Y; Feng J; Sun Y; Zhang J; Zhang G
Clin Lung Cancer; 2023 Jan; 24(1):18-28. PubMed ID: 36446703
[TBL] [Abstract][Full Text] [Related]
9. The comparison of Lobe-Specific or Systematic Mediastinal Lymph Node Dissection for Early-Stage Lung Adenocarcinoma With Consolidation Tumor Ratio Over 0.5.
Sui Q; Yang H; Yin J; Li M; Jin X; Chen Z; Jiang W; Wang Q
Clin Lung Cancer; 2023 Jan; 24(1):51-59. PubMed ID: 36153194
[TBL] [Abstract][Full Text] [Related]
10. Fasting plasma glucose and alanine aminotransferase on the risk of hepatocellular carcinoma: A nested case-control study.
Zhang L; Wang Z; Chen R; Cheng Z; Yang J; Li J; Li S; Chen Y; Xu L; Hu Y; Bai Y
Cancer Epidemiol; 2023 Jun; 84():102362. PubMed ID: 37027905
[TBL] [Abstract][Full Text] [Related]
11. Relative survival analysis of gynecological cancers in an urban district of Shanghai during 2002-2013.
Jiang YF; Jiang Y; Bi JH; Zhang Y; Zheng WW; Zhou XH; Wu J; Yuan HY; Zhao WS; Xiang YB
Cancer Epidemiol; 2023 Jun; 84():102355. PubMed ID: 36989956
[TBL] [Abstract][Full Text] [Related]
12. Study on TFF1 and PALB2 gene variants associated with gastric carcinoma risk in the Chinese Han population.
Zou W; Zhang Q; Sun R; Li X; He S
Cancer Epidemiol; 2023 Apr; 83():102333. PubMed ID: 36758349
[TBL] [Abstract][Full Text] [Related]
13. Pre-existing psychological disorders, diabetes, and pancreatic cancer: A population-based study of 38,952 Finns.
Li P; Hu Y; Scelo G; Myrskylä M; Martikainen P
Cancer Epidemiol; 2023 Feb; 82():102307. PubMed ID: 36459909
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant osimertinib and chemotherapy for stage IIIA primary pulmonary carcinosarcoma with EGFR 19DEL mutation: A case report.
Wang H; Wu Z; Du Y; Wu T; Tian W; Dong W; Cai J; Zheng J; Zhang Y; Li S; Xu W; Qin J; Xiao Z
Front Oncol; 2023; 13():1145021. PubMed ID: 36969031
[TBL] [Abstract][Full Text] [Related]
15. Impact of TP53 Mutations on EGFR-Tyrosine Kinase Inhibitor Efficacy and Potential Treatment Strategy.
Fu J; Tong Y; Xu Z; Li Y; Zhao Y; Wang T; Li C; Cang S
Clin Lung Cancer; 2023 Jan; 24(1):29-39. PubMed ID: 36117108
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
17. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer.
Stockhammer P; Grant M; Wurtz A; Foggetti G; Expósito F; Gu J; Zhao H; Choi J; Chung S; Li F; Walther Z; Dietz J; Duffield E; Gettinger S; Politi K; Goldberg SB
J Thorac Oncol; 2024 Feb; 19(2):240-251. PubMed ID: 37806385
[TBL] [Abstract][Full Text] [Related]
18. Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study.
Sun H; Ren P; Chen Y; Lan L; Yan Z; Yang Y; Wang B; Wang C; Li Y; Li L; Zhang Y; Li Y; Wang Z; Pan Z; Jiang Z
BMC Cancer; 2023 Mar; 23(1):198. PubMed ID: 36864384
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
